U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07847697) titled 'A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10' on Sept. 17.

Brief Summary: Phase Ia to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of SCTB10 following a single dose in healthy participants

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Healthy Participants

Intervention: DRUG: SCTB10

SCTB10 will be subcutaneously administered as a single dose in healthy volunteers

DRUG: Placebo

Placebo will be subcutaneously administered in Healthy Volunteers

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Sinocelltech Ltd.

Pub...